Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Omega-3 Fatty Acids and/or Multi-domain Intervention in the Prevention of Age-related Cognitive Decline (MAPT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00672685
Recruitment Status : Completed
First Posted : May 6, 2008
Last Update Posted : April 17, 2015
Sponsor:
Information provided by (Responsible Party):
University Hospital, Toulouse

Tracking Information
First Submitted Date  ICMJE May 2, 2008
First Posted Date  ICMJE May 6, 2008
Last Update Posted Date April 17, 2015
Study Start Date  ICMJE May 2008
Actual Primary Completion Date April 2014   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: April 16, 2015)
Change in cognitive function at 36 months determined by a composite score (sum of Z-score of 4 tests: FCRST test (free recall + total recall) score, MMSE orientation score, Wais-R score (Digit Substitution Symbol test), and the Category Naming Test score [ Time Frame: Baseline, 6, 12, 24, 36 months ]
Original Primary Outcome Measures  ICMJE
 (submitted: May 2, 2008)
Changes in memory function scores at 36 months determined by Gröber & Buscke test [ Time Frame: Baseline, 6, 12, 24, 36 months ]
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: May 2, 2008)
Changes in other cognitive functions. Changes in functional capacities. To study the long-term safety and tolerability of V0137 CA treatment. To study compliance and adhesion to the "multi-domain" intervention program. [ Time Frame: Baseline, 6, 12, 24, 36 months ]
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Omega-3 Fatty Acids and/or Multi-domain Intervention in the Prevention of Age-related Cognitive Decline
Official Title  ICMJE Assessment of the Efficacy of Omega-3 Fatty Acids Supplementation, Multi-domain Intervention or Their Combination on the Change of Cognitive Functions in Frail Elderly Subjects
Brief Summary

Epidemiological and fundamental research carried out in recent years has highlighted the role played by omega-3 fatty acids in the process of cognitive decline that accompanies advancing age and Alzheimer's disease. In addition, it has been recognized for some years, following several convergent studies on the prevention of cognitive decline, that nutrition, physical exercise, cognitive training and social activities play a significant role in the maintenance of cognitive faculties. At present, there are a number of epidemiological arguments in favour of a protective role of each of these factors taken in isolation. It can be postulated that a multi-domain intervention may potentiate the protective role of omega-3 fatty acids.

The main objective of this study is to assess the efficacy of isolated supplementation with omega-3 fatty acid, an isolated multi-domain intervention (nutrition, physical exercise, cognitive stimulation, social activities), or their combination on the change of cognitive functions in frail elderly subjects aged of 70 years and older over 3 years.

Secondary objectives:

  • To assess the efficacy of each treatment strategy on the change of functional capacities and the prevention of dependency,
  • To study the long-term safety and tolerability of V0137,
  • To study compliance and adhesion to the multi-domain intervention programme,

Ancillary studies :

To assess the impact of an intervention program on brain metabolism in FDG PET (MAPT-NI : : impact of multidomain intervention on brain metabolism (FDG-PET))

  • To evaluate the impact of preventive strategies (Omega-3 treatment and multidomain intervention ) of MAPT study on brain atrophy (MRI),
  • To evaluate the presence and density of ß-amyloid in MAPT subjects using AV45 PET scans (MAPT AV45),
  • To determine if sleep disorders at early stage of Alzheimer 's disease could be predictive of cognitive decline and used as diagnosis tools (Mapt SLEEP)
  • To evaluate the impact of omega-3 fatty acids on the body composition measured by DXA scans (MAPT-DXA)
Detailed Description

This is a multi-centre , randomised, placebo-controlled study in parallel groups in 1680 frail elderly subjects over the age of 70 years, living at home, monitored for a period of 3 years. The subjects will be randomised into one of the following 4 groups:

  • Omega-3 group: 800 mg/day of docosahexaenoic acid (V0137CA nutritional supplement)
  • Omega-3 + multi-domain intervention group: 800 mg/day of docosahexaenoic acid ( V0137CA)
  • Placebo + multi-domain intervention group
  • Placebo group The multi-domain intervention includes training / information sessions in the following 4 areas: nutrition, physical activity, cognitive training and social activities, and preventive consultations.

Selected subjects will present at least one of the following frailty criteria:

  • Loss of one Instrumental Activity Daily Living (IADL)
  • Subjective memory complaints to a physician
  • Slow walking speed. Follow-up visits will occur every six months for 3 years for both dispensing of supplement and compliance (months 6, 12, 18, 24, 30 and 36) and neuropsychological and functional assessment (months 6, 12, 24, 36).
Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Condition  ICMJE Frail Elderly Subjects
Intervention  ICMJE
  • Dietary Supplement: omega-3
    V0137 CA containing 400 mg docosahexaenoic acid (DHA) - 2 soft capsules once a day, i.e. 800 mg DHA per day for 36 months
    Other Name: Omega-3 fatty acids
  • Behavioral: multi-domain intervention
    multi-domain intervention = Nutrition, physical exercise, cognitive training and social activities, and preventive consultations
  • Drug: Placebo
    OMEGA-3 placebo
Study Arms  ICMJE
  • Experimental: 1
    Omega-3 group without any intervention
    Intervention: Dietary Supplement: omega-3
  • Experimental: 2
    Omega-3 combined group (Omega-3 + multi-domain intervention)
    Interventions:
    • Dietary Supplement: omega-3
    • Behavioral: multi-domain intervention
  • Experimental: 3
    Placebo combined group (Placebo + multi-domain intervention)
    Interventions:
    • Behavioral: multi-domain intervention
    • Drug: Placebo
  • Placebo Comparator: 4
    Placebo group without any intervention
    Intervention: Drug: Placebo
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: June 16, 2010)
1680
Original Estimated Enrollment  ICMJE
 (submitted: May 2, 2008)
1200
Actual Study Completion Date  ICMJE April 2014
Actual Primary Completion Date April 2014   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • subjects of both sex, aged of 70 years or over,
  • subjects with at least one of the following frailty criteria: a subjective memory complaint, expressed to their attending physician, an inability to perform one of instrumental activities of daily living, a slow walking with a speed ≤ 0.77 m/s, i.e 5 seconds to walk 4 meters.
  • subjects with an MMSE score of greater than or equal to 24,
  • subjects capable of understanding the protocol, complying with its requirements and attending the study visits,
  • subjects with sufficient availability to take part in the multi-domain intervention programme,
  • subjects who, in the opinion of the investigator, are liable to comply with the treatment during the study;
  • subjects capable of giving their written informed consent
  • Covered by a health insurance system

Exclusion Criteria:

  • Criteria related to diseases:

    • known presence of dementia or Alzheimer's disease (DSM IV criteria),
    • deterioration in global cognitive function (MMSE < 24),
    • dependency for basic activities of daily living (ADL<6),
    • presence of serious diseases, which could be life-threatening in the short term,
    • history or presence of any disease that could compromise the subject's participation in the multi-domain intervention sessions,
  • Criteria related to treatments:

    o taking of supplements containing omega-3 (apart from food) within the past 6 months and/or taking omega-3 at inclusion.

  • Criteria related to subjects:

    • visual or hearing impairments incompatible with performance and/or interpretation of the neuropsychological tests,
    • history or presence of any previous pathologies that could, in the opinion of the investigator, interfere with the results of the study or expose the subject to an additional risk,
    • subjects deprived of their freedom by administrative or judicial decision, or under guardianship or admitted to a healthcare or social institution,
    • participation in another clinical study in the previous month or participation scheduled during the study.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 70 Years and older   (Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE France,   Monaco
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00672685
Other Study ID Numbers  ICMJE 07 116 03
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party University Hospital, Toulouse
Study Sponsor  ICMJE University Hospital, Toulouse
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Bruno Vellas, MD-PhD Toulouse University Hospital Centre
PRS Account University Hospital, Toulouse
Verification Date April 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP